Pfizer’s MagnetisMM Trials for Multiple Myeloma
Together we can make a difference
Your patients don’t have to take on multiple myeloma (MM) alone.
We know it takes a full support system to treat multiple myeloma, and we’re here to explore potential treatments with you.
Pfizer has several ongoing clinical trials assessing a potential therapy for patients with multiple myeloma. These clinical trials are part of the MagnetisMM program.
The MagnetisMM clinical research studies will evaluate the safety and effectiveness of a study medicine, elranatamab, in people with multiple myeloma. The investigational study medicine, elranatamab, is a bispecific antibody designed to bind to B-cell maturation antigen (BCMA) – which is highly expressed on the surface of multiple myeloma cells – and the CD3 receptor found on the surface of cancer-fighting T cells, bridging them together to activate an immune response.
Elranatamab has already been granted accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Read more here:
For more information about Pfizer’s enrolling multiple myeloma clinical trials, please click the Learn More button.
What is multiple myeloma?
Multiple myeloma is a haematological B-cell malignancy characterized by dysregulated proliferation of BM plasma cells. Globally, there are approximately 176,000 new cases and 117,000 deaths per year attributed to multiple myeloma.1 The American Cancer Society estimates that for the US in 2021, approximately 34,920 new multiple myeloma cases will be diagnosed and approximately 12,410 multiple myeloma related deaths will occur.2
Despite recent advances in treatment, multiple myeloma remains an incurable disease and almost all patients, even those who initially respond to treatment, are expected to relapse.
1 1 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
2 American Cancer Society. Cancer Facts & Figures. 2021. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annualcancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed: 10 January 2021.
2 American Cancer Society. Cancer Facts & Figures. 2021. Available from: https://www.cancer.org/content/dam/
cancer-org/research/cancer-facts-and-statistics/annualcancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed: 10 January 2021.
Do you have potentially eligible patients with multiple myeloma in your care?
They may be eligible for one of Pfizer’s MagnetisMM Trials for multiple myeloma.
To find out more about the multiple myeloma investigational medicine, multiple myeloma clinical trials, and how to refer potentially eligible patients, please complete the Contact Form below and a member of the Pfizer [Field Medical] team will contact you.
This contact form is intended to be completed by healthcare professionals only. Please DO NOT submit any patient data in the contact form.
Pfizer’s investigational medicine for multiple myeloma
Elranatamab
Elranatamab is an investigational bispecific antibody. Targeted T-cell-mediated cytotoxicity occurs when elranatamab binds to T-cells and myeloma cells. Elranatamab is approved in certain countries as a treatment for patients with relapsed or refractory (RR) multiple myeloma who have received multiple prior lines of therapy. It is administered as a subcutaneous injection.
Why consider elranatamab?
Click below to view a video on BCMA as a target for multiple myeloma treatment
Why refer a patient?
Clinical trials may be an option your patients will want to consider. While no benefit is guaranteed from an investigational medicine, your patients who participate in one of our clinical trials will contribute to the process of gathering more data on this potential therapy as well as potential combinations. Your patients will also receive regular medical assessments and support throughout their study participation.
By referring patients who may be eligible to participate in one of Pfizer’s Multiple Myeloma Clinical Trials, you are helping to further research on the treatment of multiple myeloma and you as an HCP are building connections to clinical research.
For more information about Pfizer’s enrolling multiple myeloma clinical trials, please click the Learn More button.
Importance of diversity
Many factors, including race, ethnicity, age, and gender, can all impact how different people respond to the same treatment. Therefore, participant diversity in clinical trials is crucial in order to understand whether investigational medicines are effective for all patients.
At Pfizer, we are committed to creating change for the better by doing our part to make clinical research more inclusive.
Ensuring diversity in clinical trials is a matter of equity. We have made a commitment to design clinical trials for participation to reflect the populations of all communities, including the people most affected by the diseases we intend to treat or prevent. Together, we can make medicines better for all.
Please consider diverse patients and patients from communities typically underrepresented in clinical trials as you think about potential patients to refer for clinical trial participation. It is important to test for differences in outcomes and to help ensure the safety and effectiveness of therapies. Accurate representation of patients of all backgrounds in clinical trials can help to improve the drug development process and reduce health disparities among underrepresented populations.
EN-US 
EN-AU 
CS 
FR-FR 
EN-GB